Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1661-1667

  Teicher, Beverly A ^a   Ara, Gulshan ^a   Buxton, David ^a   Leonard, John ^b   Schaub, Robert G ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; DOSE RESPONSE; DRUG SENSITIVITY; MELANOMA; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; IMMUNOLOGIC FACTORS; INTERLEUKIN-12; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 0030795160     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Banks, R. E., Patel, P. M., and Selby, P. J. Interleukin 12: a new clinical player in cytokine therapy. Br. J. Cancer, 71: 655-659, 1995.
2. Gazzinelli, R. T., Hieny, S., Wynn, T. A., Wolf, S., and Sher, A. Interleukin 12 is required for the Tlymphocyte-independent induction of Interferon γ by an intracellular parasite and induces resistance in T cell-deficient hosts. Proc. Natl. Acad. Sci. USA, 90: 6115-6119, 1993.
3. Locksley, R. M. Interleukin 12 in host defense against microbial pathogens. Proc. Natl. Acad. Sci. USA, 90: 5879-5880, 1993.
4. Robertson, M., and Ritz, J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist, 1: 88-97, 1996.
5. Gately, M. K., Desai, B., Wolitzky, A. G., Quinn, P. M., Dwyer, C. M., Podlaski, F. J., Familletti, P. C., Sinigaglia, F., Chizzonite, R., Gubler, U., and Stern, A. S. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol., 147: 874-882, 1991.
6. + T lymphocytes, and NK cells. J. Immunol., 149: 3495-3502, 1992.
7. Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donahue, C., Young, D., Herrmann, S. H., and Ritz, J. Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med., 175: 779-788, 1992.
8. Gately, M. K., Wolitzky, A. G., Quinn, P. M., and Chizzonite, R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell. Immunol., 143: 127, 1992.
9. + NK cells. J. Immunol., 148: 2429-2436, 1992.
10. Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospisil, M., Young, H. A., Wolf, S. F., Young, D., Clark, S. C., and Trinchieri, G. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responding cells and synergy with other inducers. J. Exp. Med., 173: 869-879, 1991.
11. Brunda, M., Luistro, L., Rumennik, L., Wright, R., Dvorozniak, M., Aglione, A., Wigginton, J., Wiltrout, R., Hendrzak, J., and Palleroni, A. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol., 38 (Suppl): S16-S21, 1996.
12. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of Interleukin-12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
13. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153: 1697-1706, 1994.
14. Noguchi, Y., Richards, E. C., Chen, Y-T., and Old, L. J. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA, 92: 2219-2223, 1995.
15. Fujiwara, H., and Hamaoka, T. Antitumor and antimetastatic effects of interleukin 12. Cancer Chemother. Pharmacol., 38: S22-S26, 1996.
16. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., and Folkman, J. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. (Bethesda), 87: 581-586, 1995.
17. Kedar, E., and Klein, E. Cancer immunotherapy: are the results discouraging? Can they be improved? Adv. Cancer Res., 59: 245-322, 1992.
18. Seder, R. A., Gazzinelli, R., Sher, A., and Paul, W. E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA, 90: 10188-10192, 1993.
19. Yoshida, A., Koide, Y., Uchijima, M., and Yoshida, T. O. IFN-γ induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem. Biophys. Res. Commun., 198: 857-861, 1994.
20. Gately, M. K., Warrier, R. R., Honasoge, S., Carvajal, D. M., Faherty, D. A., Connaughton, S. E., Anderson, T. D., Sarmiento, U., Hubbard, B. R., and Murphy, M. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol., 6: 157-167, 1994.
21. Zeh, H. J., III, Hurd, S., Storkus, W. J., and Lotze, M. T. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J. Immunother., 14: 155-161, 1993.
22. Caruso, M., Pham-Nguyen, K., Kwong, Y., Xu, B., Kosai, K., Finegold, M., Woo, S., and Chen, S. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA, 93: 11302-11306, 1996.
23. Nishimura, T., Watanabe, K., Yahata, T., Uede, T., Saiki, I., Herrmann, S. H., Kobayashi, M., and Habu, S. The application of IL-12 to cytokine therapy and gene therapy for tumors. Ann. N.Y. Acad. Sci., 795: 375-378, 1996.
24. Brunda, M. J. Interleukin-12. J. Leuk. Biol., 55: 280-288, 1994.
25. Teicher, B. A., Ara, G., Menon, K., and Schaub, R. G. In vivo studies with interleukin-12 alone and in combination with monocyte-colony stimulating factor and/or fractionated radiation therapy. Int. J. Cancer, 65: 80-84, 1995.
26. Teicher, B., Ara, G., Buxton, D., Leonard, J., and Schaub, B. Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Int. J. Cancer, submitted, 1997.
27. Gohji, K., Fidler, I., Tsan, R., Radinsky, R., von Eschenbach, A., Tsuruo, T., and Nakajima, M. Human recombinant interferons-β and γ decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int. J. Cancer, 58: 380-384, 1994.
28. r 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons α and γ in human melanoma. Int. J. Cancer. 58: 582-586, 1994.
29. Norioka, K., Mitaka, T., Mochizuki, Y., Hara, M., Kawagoe, M., and Nakamura, H. Interaction of interleukin 1 and interferon-γ on fibroblast growth factor-induced angiogenesis. Jpn. J. Cancer Res., 85: 522-529, 1994.
30. Hiscox, S., Hallett, M. B., Puntis, M. C. A., and Jiang, W. G. Inhibition of cancer cell motility and invasion by interleukin-12. Clin. & Exp. Metastasis, 13: 396-404, 1995.
31. Wigginton, J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J., and Wiltrout, R. H. Administration of interleukin-12 with pulse interleukin-2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. (Bethesda), 88: 38-43, 1996.
32. Lu, L., Shen, R-N., Lin, Z-H., Aukerman, S. L., Ralph, P., and Broxmeyer, H. E. Anti-tumor effects of recombinant human macrophage colony-stimulating factor, alone or in combination with local irradiation, in mice inoculated with Lewis lung carcinoma cells. Int. J. Cancer. 47: 143-147, 1991.
33. Bonta, I. L., and Ben-Efraim, S. Involvement of inflammatory mediators in macrophage antitumor activity. J. Leuk. Biol., 54: 613-626, 1993.
34. Wolf, S. F., Sieburth, D., and Sypek, J. Interleukin 12: a key modulator of immune function. Stem Cells, 12: 154-168, 1994.
35. Munn, D. H., and Cheung, N. K. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor: induction of efficient antibody mediated antitumor cytotoxicity not detected by isotope release assays. J. Exp. Med., 170: 511-526, 1989.